Table 3.

The results of phase 3 trials evaluating the efficacy of immune checkpoint inhibitors to SCCHN other than KEYNOTE-048

Trial	Patient setting	Treatment arm	OS Hazard ratio (95% CI)	p-value	Reference
JAVELIN Head & Neck 100	Locally advanced	CRT with or without Avelumab	1.31 (0.93–1.85)	0.937	[62]
CheckMate 141	Recurrent/metastatic, 2nd line	Nivolumab vs physicians’ choice*	0.70 (0.51–0.96)	0.01	[51]
KEYNOTE-040	Recurrent/metastatic, 2nd line	Pembrolizumab vs physicians’ choice	0.80 (0.65–0.98)	0.0161	[52]
EAGLE	Recurrent/metastatic, 2nd line	Durvalumab vs standard care**	0.88 (0.72–1.08)	0.20	[56]
		Durvalumab plus tremelimumab vs standard care	1.04 (0.85–1.26)	0.76

*Methotrexate, docetaxel or cetuximab. **Methotrexate, docetaxel, paclitaxel, cetuximab, 5-fluorouracil, TS-1 or capecitabine